Tagged with Pricing

Bulgaria Assena Stoimenova, member of the management board of the European Medicines Agency (EMA) and executive director of the Bulgarian Drug Agency (BDA), explains the Agency’s evolution under her tenure as well as her commitment to ensuring that the BDA remains predictable, transparent and fair, being fully focused on safeguarding patients…

Austria Dr. Jan Oliver Huber, secretary general of the Association of the Pharmaceutical Industry in Austria, or PHARMIG, which represents 120 member companies and 95 percent of the medicinal product market in Austria, discusses the changing dynamics of the Austrian healthcare sector and its price referencing system. He also gives his…

USA In an exclusive interview, Stephen Ubl, President and CEO of the Pharmaceutical Researchers and Manufacturers of America (PhRMA), the association representing the leading innovative biopharmaceutical companies in the USA, discusses the onset of a new “golden era” in medicine. He goes on to discuss pricing issues, engaging in a constructive…

Colombia Alejandro Gaviria Uribe, Colombia’s minister of health and social protection, discusses the implementation of the Statutory Health Law, bridging the gap between healthcare coverage and access to healthcare, and the strategic priorities of the Ministry moving forward. In our 2013 interview, your overarching sentiment was that the healthcare landscape was…

Colombia With over a decade as executive director of the Pharmaceutical Chamber of ANDI (The Colombian National Business Association), Rodrigo Arcila Gomez, shares his optimistic insights on the growth of the sector, the current status of pricing negotiations, his key achievements, and the need for a pharmaceutical landscape built on trust.…

Colombia Héctor Castro, director of Medicines and Health Technologies at the Colombian Ministry of Health since 2016, explains how the regulations and quality standards implemented have contributed to make Colombia’s healthcare system one of the best in Latin America. You were appointed director of Medicines and Health Technologies at the Ministry…

Greece As the Executive Director of the American-Hellenic Chamber, Elias Spirtounias, is a believer in solutions. He speaks about ensuring the resiliency of the bi-lateral American and Greek relationship throughout transformative times, focusing on garnering investments for the sector, as well as creating spaces for collaboration amongst all relevant parties to…

Greece  Astellas Greece & Cyprus MD, Harry Nardis, emphasizes the importance of integrity, compliance and innovation to the Astellas business model, key priorities, navigating the Greek pharmaceutical landscape while maintaining a high-quality reputation, and retaining the company’s vision of being at the forefront of healthcare change. Having assumed the leadership position…

Switzerland Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics touched upon by KPMG Switzerland’s head of life sciences Martin Rohrbach. On February 12th the Swiss people rejected the Tax…

Greece “There is nothing so stable as change” says chairman of the medical devices and diagnostics committee for the American Chamber of Commerce and GM for J&J Medical Hellas, Theodore Liakopoulos. Having spearheaded the affiliate through the economic crisis, Liakopoulos speaks candidly about his strategic priorities, the importance of staying agile to…

Greece With a dual role as the president of SFEE (Hellenic Association of Pharmaceutical Companies) and the General Manager of one of the most innovative biopharmaceutical companies in the world, Abbvie, Pascal Apostolides candidly discusses the milestones of Abbvie as an independent company, the impact of clawbacks and rebates in the…

Greece Outspoken, charismatic and dedicated General Manager of Pierre-Fabre Greece, Philippe Lambrinos, shares his insights on the company’s presence and performance in the challenging Greek market, how it’s manoeuvring issues of market access and clawbacks, as well as his overarching vision for Pierre-Fabre in Greece. Mr. Lambrinos, you have spent 21…